18F-fluoromethylcholine or 18F-fluoroethylcholine pet for prostate cancer imaging: Which is better? A literature revision

Nuclear Medicine and Biology

Volumn 42, Issue 4, 2015, Pages 340-348

  Evangelista, Laura ^a   Cervino, Anna Rita ^a   Guttilla, Andrea ^b   Zattoni, Fabio ^b   Cuccurullo, Vincenzo ^c   Mansi, Luigi ^c  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Diagnostic accuracy; Fluoethylcholine; Fluoromethylcholine; PET imaging; Prostate cancer

Indexed keywords

FLUOROETHYLCHOLINE F 18; FLUOROMETHYLCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; FLUOROETHYLCHOLINE; FLUOROMETHYLCHOLINE;

ANDROGEN DEPRIVATION THERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; HUMAN; LYMPH NODE METASTASIS; MONITORING; PROSTATE CANCER; REVIEW; SENSITIVITY ANALYSIS; SURGICAL APPROACH; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; MALE; META ANALYSIS; METABOLISM; PROCEDURES; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

CHOLINE; DIAGNOSTIC IMAGING; HUMANS; MALE; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84924905659     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.12.019     Document Type: Review

References (48)

1. Mertens K., Slaets D., Lambert B., Acou M., De Vos F., Goethals I. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging 2010, 37:2188-2193.
2. Hara T., Bansal A., DeGrado T.R. Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 2006, 5:498-509.
3. Ramírez de Molina A., Rodriguez-Gonzalez A., Gutiérrez R., Martínez-Piñeiro L., Sánchez J., Bonilla F., et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002, 296:580-583.
4. Yoshimoto M., Watanabe I.S., Martins M.T., Salles M.B., Ten Eyck G.R., Coelho P.G. Microstructural and ultrastructural assessment of inferior alveolar nerve damage following nerve lateralization and implant placement: an experimental study in rabbits. Int J Oral Maxillofac Implants 2009, 24:859-865.
5. Cho S.Y., Szabo Z. Molecular imaging of urogenital diseases. Semin Nucl Med 2014, 44:93-109.
6. Authors N.L. FDA approves 11C-choline for PET in prostate cancer. J Nucl Med 2012, 53:11N.
7. Tuncel M., Souvatzoglou M., Herrmann K., Stollfuss J., Schuster T., Weirich G., et al. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008, 35:689-695.
8. Castellucci P., Fuccio C., Rubello D., Schiavina R., Santi I., Nanni C., et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5ng/ml?. Eur J Nucl Med Mol Imaging 2011, 38:55-63.
9. Hara T., Yamamoto M. Automated synthesis of fluorine-18 labeled choline analogue: 2-fluoroethyl-dimethyl-2-oxyethylammonium. J Nucl Med 1997, 38:44P. [abstract, suppl].
10. Hara T., Kosala N., Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002, 43:187-199.
11. DeGrado T.R., Coleman R.E., Wang S., Baldwin S.W., Orr M.D., Robertson C.N., et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001, 61:110-117.
12. Uusijärvi H., Nilsson L.E., Bjartell A., Mattsson S. Biokinetics of 18F-choline studied in four prostate cancer patients. Radiat Prot Dosimetry 2010, 139:240-244.
13. Graute V., Jansen N., Ubleis C., Seitz M., Hartenbach M., Scherr M.K., et al. Relationship between PSA kinetics and (18F)fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012, 39:271-282.
14. Tilki D., Reich O., Graser A., Hacker M., Silchinger J., Becker A.J., et al. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 2013, 63:792-796.
15. Steuber T., Schlomm T., Heinzer H., Zacharias M., Ahyai S., Chun K.F., et al. [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur J Cancer 2010, 46:449-455.
16. Würschmidt F., Petersen C., Wahl A., Dahle J., Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 2011, 6:1-8. [44].
17. Poulsen M.H., Bouchelouche K., Høilund-Carlsen P.F., Petersen H., Gerke O., Steffansen S.I., et al. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int 2012, 110:1666-1671.
18. Beheshti M., Imamovic L., Broinger G., Vali R., Waldenberger P., Stoiber F., et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010, 254:925-933.
19. Beheshti M., Haim S., Zakavi R., Steinmair M., Waldenberger P., Kunit T., et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 2013, 54:833-840.
20. Husarik D.B., Miralbell R., Dubs M., John H., Giger O.T., Gelet A., et al. Evaluation of (18F)-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:253-263.
21. Cimitan M., Bortoluss R., Morassut S., Canzonieri V., Garbeglio A., Baresic T., et al. (18F)fluorocholine PET/CT imaging for the detection of recurrent cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006, 33:1387-1398.
22. Wetter A., Lipponer C., Nensa F., Beiderwellen K., Olbricht T., Rübben H., et al. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol 2013, 48:256-262.
23. Poulsen M.H., Bouchelouche K., Gerke O., Petersen H., Svolgaard B., Marcussen N., et al. [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2010, 106:639-643.
24. Häcker A., Jeschke S., Leeb K., Prammer K., Ziegerhofer J., Sega W., et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006, 176:2014-2019.
25. Kwee S.A., Lim J., Watanabe A., Kromer-Baker K., Coel M.N. Prognosis related to metastatic burden measured by 18F-fluorocholine PET/CT in castration-resistant prostate cancer. J Nucl Med 2014, 55:905-910.
26. Buchegger F., Garibotto V., Zilli T., Allainmant L., Jorcano S., Vees H., et al. First imaging results of an intraindividual comparison of 11C-acetate and 18F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging 2014, 41:68-78.
27. Marzola M.C., Chondrogiannis S., Ferretti A., Grassetto G., Rampin L., Massaro A., et al. Role of 18F-choline PET/CT in biochemically relpased prostate cancer after radical prostatectomy. Clin Nucl Med 2013, 38:e26-e32.
28. Henninger B., Vesco P., Putzer D., Kendler D., Loizides A., Bale R.J. (18F)choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy - a preliminary study. Nucl Med Commun 2012, 33:889-894.
29. Oprea-Lager D.E., Vincent A.D., van Moorselaar R.J., Gerritsen W.R., van den Eertwegh A.J., Eriksson J., et al. Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. PLoS One 2012, 7:1-9. [e48430].
30. Hodolic M. Role of 18F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol 2011, 45:17-21.
31. Schillaci O., Calabria F., Tavolozza M., Ragano Caracciolo C., Finazzi Agrò E., Miano R., et al. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 2012, 39:589-596.
32. Soyka J.D., Muster M.A., Schmid D.T., Seifert B., Schick U., Miralbell R., et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2012, 39:936-943.
33. Pinkawa M., Holy R., Piroth M.D., Klotz J., Nussen S., Krohn T., et al. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 2010, 186:600-606.
34. Kjolhede H., Ahlgren G., Almquist H., Liedberg F., Lyttkens K., Ohlsson T., et al. 18F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. World J Urol 2014, 32:965-970.
35. Gacci M., Cai T., Siena G., Minervini A., Torshizi M.F., Bartolini M., et al. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: results from a longitudinal cohort study. Scand J Urol 2014, 48:259-267.
36. McCarthy M., Slew T., Campbell A., Lenzo N., Spry N., Vivian J., et al. 18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 2011, 38:14-22.
37. Beheshti M., Vali R., Waldenberger P., Fitz F., Nader M., Loidl W., et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008, 35:1766-1774.
38. Vees H., Buchegger F., Albrech S., Khan H., Husarik D., Zaidi H., et al. 18F-choline and 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate specific antigen values (<1ng/mL) after radical prostatectomy. BJU Int 2007, 99:1415-1420.
39. Panebianco V., Sciarra A., Lisi D., Galati F., Buonocore V., Catalano C., et al. Prostate cancer: 1HMRS-DCEMR at 3T versus (18F)choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 2012, 81:700-708.
40. Afshar-Oromieh A., Haberkorn U., Schlemmer H.P., Fenchel M., Eder M., Eisenhut M., et al. Comparison of PET/CT and PET/MRI hybrid systems using a (68)Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2014, 41:887-897.
41. Pelosi E., Arena V., Skanjeti A., Pirro V., Douroukas A., Pupi A., et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008, 113:895-904.
42. Hara T., Bansal A., DeGrado T.R. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006, 33:977-984.
43. Fuccio C., Schiavina R., Castellucci P., Rubello D., Martorana G., Celli M., et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011, 38:1985-1989.
44. Mansi L., Cuccurullo V., Evangelista L. Is radiocholine PET/CT already clinically useful in patients with prostate cancer?. J Nucl Med 2014, 55:1401-1403.
45. Takesh M. Kinetic modeling application to 18F-fluoroethylcholine positron emission tomography in patients with primary and recurrent prostate cancer using two-tissue compartmental model. World J Nucl Med 2013, 12:101-110.
46. Witney T.H., Alam I.S., Turton D.R., Smith G., Carroll L., Brickute D., et al. Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography. Clin Cancer Res 2012, 18:1063-1072.
47. Filice A., Asti M., Roncali M., Fraternali A., Casali M., Di Paolo M., et al. Comparison between the physiological distribution of 18F-FMCH and 18F-FECH. Eur J Nucl Med Mol Imaging Suppl 2010, 37:P466. [abstract, suppl].
48. DeGrado T.R., Baldwin S.W., Wang S., Orr M.D., Liao R.P., Friedman H.S., et al. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001, 42:1805-1814.